SNMMI Radioluminescence Single Cells Nuclear Imaging

With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).

Taking their pick, biomedical researchers can now conduct five different imaging studies in one scan with a state-of-the-art preclinical molecular imaging system that scientists unveiled during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

Low back pain is not only excruciating but also debilitating for countless sufferers. Unfortunately, not everyone responds to treatment. A molecular imaging scan in addition to a conventional bone scan can provide the necessary information about the physiological health of the spine to select the most appropriate pain-killing treatment protocol, say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).

June 9, 2014 — Toshiba America Medical Systems Inc. announced the release of its Celesteion system for positron emission tomography/computed tomography (PET/CT) imaging. The Celesteion is currently pending 510(k) clearance from the U.S. Food and Drug Administration (FDA).

June 9, 2014 — After conducting a functional magnetic resonance imaging (fMRI) study on memory and categorization, researchers have shown for the first time that these mathematical models seem to correctly explain processing in the medial temporal lobes, a region of the brain associated with long-term memory that is disrupted by memory disorders like Alzheimer’s disease. The findings were published in The Journal of Neuroscience.

The prominent role a single enzyme plays in cancer imaging has eluded researchers for years, but not anymore. This discovery could pave new avenues in nuclear medicine. 

June 9, 2014 — ImaginAb Inc., in collaboration with Memorial Sloan-Kettering Cancer Center, will present at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) initial clinical data with an anti-PSMA (prostate-specific membrane antigen) recombinant antibody fragment (a "minibody") derived from the huJ591 monoclonal antibody, in patients with metastatic prostate cancer.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now